The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Drug Therapy
PreviousPrevious
Volume 354:483-495 February 2, 2006 Number 5
NextNext

Coronary-Artery Stents
Patrick W. Serruys, M.D., Ph.D., Michael J.B. Kutryk, M.D., Ph.D., and Andrew T.L. Ong, M.B., B.S.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The use of percutaneously introduced prosthetic devices to maintain the luminal integrity of diseased blood vessels was proposed by Dotter and Judkins in 1964,1 well before the introduction of coronary angioplasty by Grüntzig et al. in 1977.2 Palmaz et al. introduced the use of balloon-mounted stents (as used in coronary arteries today) in peripheral arteries in 1985.3 Schatz et al. subsequently modified the Palmaz stent, which led to the development of the first commercially successful stent, the Palmaz–Schatz stent.4 Puel and Sigwart were the first to implant a stent in humans in March 1986; they used a self-expanding mesh device. . . . [Full Text of this Article]

Barrier and Bioactive Stent Coatings

Barrier Stent Coatings

Active Stent Coating to Prevent Thrombosis

Drug-Eluting Stents

Successful Drug-Eluting Stents

            Sirolimus-Eluting Stents

            Polymeric Paclitaxel–Eluting Stents

Real-World Experience

Comparative Trials

Investigative Agents

            Zotarolimus

            Everolimus

            Other Agents

Indications for the Use of Coronary Stents

Primary Revascularization after Myocardial Infarction Involving ST-Segment Elevation

            Focal Lesions in Vessels 3.0 mm or More in Diameter

            Focal Lesions in Saphenous-Vein Grafts

            Treatment of Chronic Total Occlusions

            Treatment of Restenosis after Balloon Angioplasty

Segmental Lesions for Which Coronary Stenting is Probably Beneficial

            Long Lesions

            Small Vessels

            Lesions at Bifurcations

Unresolved Issues

            Stenosis of an Unprotected Left Main Coronary Artery

            Multivessel Disease

            Diabetes Mellitus

            In-Stent Restenosis

            Biodegradable Stents

Caveats and Conclusions


Source Information

From the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands (P.W.S., A.T.L.O.); and the University of Toronto, St. Michael's Hospital, Toronto (M.J.B.K.).

Address reprint requests to Dr. Serruys at the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.


Related Letters:

Coronary-Artery Stents
Silverman M. E., Kounis N. G., Kounis G. N., Kouni S. N., Taggart D. P., Serruys P. W., Ong A. T.L.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2076-2078, May 11, 2006. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.